Michael F. Jantsch, Ângela S. Marques
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Site-directed RNA editing: recent advances and open challenges
10.1080/15476286.2021.1983288 · 2021
The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk–reducing therapies to the novel challenging strategies
10.1016/j.pharmr.2025.100086 · 2025
ADAR RNA editing for cardiovascular disease: Targeting B4GALT1 to modulate lipid metabolism through reduced galactosyltransferase activity
10.1016/j.omtn.2026.103001 · 2026
Therapeutic Gene Editing in Dyslipidemias
10.31083/j.rcm2508286 · 2024
Genetic and functional evidence links a missense variant in B4GALT1 to lower LDL and fibrinogen
10.1126/science.abe0348 · 2021
Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis
10.1093/cvr/cvaa252 · 2021
B4GALT1-congenital disorders of glycosylation presents as a non-neurologic glycosylation disorder with hepatointestinal involvement
10.1016/j.jpeds.2011.08.007 · 2011
Growth retardation and early death of beta-1,4-galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells
10.1093/emboj/16.8.1850 · 1997
Programmable RNA Editing via Adenosine Deaminase Acting on RNA Enzymes: Current Advances and Clinical Potential
10.1177/21593337251415115 · 2026
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
10.1021/acs.bioconjchem.3c00174 · 2023
No additional external references are available.
